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MPH compared to NFB and PA, as reflected by decreased 
response speed during the oddball task [ηp
2 = 0.21, 
p < 0.001], as well as improved inhibition, impulsivity and 
attention, as reflected by faster stop signal reaction times, 
lower commission and omission error rates during the stop-
signal task (range ηp
2 = 0.09–0.18, p values <0.008). Work-
ing memory improved over time, irrespective of received 
treatment (ηp
2 = 0.17, p < 0.001). Overall, stimulant medi-
cation showed superior effects over NFB to improve neu-
rocognitive functioning. Hence, the findings do not support 
theta/beta training applied as a stand-alone treatment in 
children with ADHD.
Keywords ADHD · Neurocognition · Medication · 
Neurofeedback · Physical activity
Introduction
Attention deficit hyperactivity disorder (ADHD) is a highly 
prevalent neurodevelopmental disorder [1] characterized by 
age-inappropriate symptoms of inattention, hyperactivity 
and impulsivity [2]. Impaired neurocognitive functioning is 
considered a core dysfunction of the disorder [3, 4] and is 
reflected in deficiencies in a variety of neurocognitive func-
tions including attention, inhibition, and working memory 
[5–8]. Stimulant medication is a commonly used and effec-
tive treatment in reducing behavioral symptoms [9] and 
has also been found to improve neurocognitive functioning 
[10] in children with ADHD. However, the use of stimulant 
medication has several adverse side effects such as sleep 
problems, decreased appetite, and headaches [11]. Moreo-
ver, there is limited evidence of long-term efficacy of stim-
ulant medication [12]. Neurofeedback has been proposed 
to be a potentially effective non-pharmacological treatment 
Abstract Neurofeedback (NFB) is a potential alterna-
tive treatment for children with ADHD that aims to opti-
mize brain activity. Whereas most studies into NFB have 
investigated behavioral effects, less attention has been paid 
to the effects on neurocognitive functioning. The present 
randomized controlled trial (RCT) compared neurocog-
nitive effects of NFB to (1) optimally titrated methylphe-
nidate (MPH) and (2) a semi-active control intervention, 
physical activity (PA), to control for non-specific effects. 
Using a multicentre three-way parallel group RCT design, 
children with ADHD, aged 7–13, were randomly allocated 
to NFB (n = 39), MPH (n = 36) or PA (n = 37) over a 
period of 10–12 weeks. NFB comprised theta/beta train-
ing at CZ. The PA intervention was matched in frequency 
and duration to NFB. MPH was titrated using a double-
blind placebo controlled procedure to determine the opti-
mal dose. Neurocognitive functioning was assessed using 
parameters derived from the auditory oddball-, stop-sig-
nal- and visual spatial working memory task. Data collec-
tion took place between September 2010 and March 2014. 
Intention-to-treat analyses showed improved attention for 
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for ADHD with effects comparable to stimulant medication 
[13, 14].
Neurofeedback aims to optimize brain activity, by pro-
viding the patient with visual and/or auditory feedback of 
electroencephalogram (EEG) activity, which is suggested 
to result in enhanced neurocognitive functioning that in 
turn translates into improved behavioral functioning [15]. 
Children with ADHD have been found to show increased 
theta (4–8 Hz) and decreased beta (13–20 Hz) activity in 
EEG measures of brain activity [16]. Increased theta and 
decreased beta activity have been related to poor vigilance 
and reduced attention, respectively [17]. A protocol that is 
often used in ADHD treatment, aims at decreasing theta 
activity and increasing beta activity [14, 18].
Results of randomized controlled trials (RCTs) on the 
effects of neurofeedback are mixed for neurocognitive out-
come measures [19–27]. Overall, double-blinded RCTs 
revealed no additional effect of neurofeedback over sham-
neurofeedback on neurocognitive measures [19, 23, 28]. 
One single-blinded RCT [20] showed superiority of neu-
rofeedback over electromyography (EMG)-biofeedback 
on attention measures. Bink et al. [21] compared treat-
ment as usual combined with neurofeedback to treatment 
as usual, and found no additional value of neurofeedback 
on measures of attention and working memory. In contrast, 
the study by Steiner et al. [29] found improved executive 
functioning in children with ADHD who received addi-
tional neurofeedback treatment compared to those who 
received only treatment as usual. A recent meta-analysis 
shows that overall neurofeedback does not induce signifi-
cantly improved neurocognitive functioning compared to 
(active) control conditions [30]. However, studies compar-
ing neurofeedback to stimulant medication on neurocogni-
tive measures are scarce. There is only one RCT [31] that 
compared effects of neurofeedback with stimulant medica-
tion as stand-alone treatments on neurocognitive function-
ing, as assessed using measures of attention and executive 
functioning. In that study, the 16 children who received 
stimulant medication, showed larger improvement in neu-
rocognitive functioning than the 16 children who received 
neurofeedback. However, the study was hampered by small 
sample size, a broad age range of participants (7 through 
16 years), wide distribution of the 30 neurofeedback ses-
sions over an intervention period of 6–9 months, and lack 
of transfer strategies into daily life. In the current study, we 
addressed these shortcomings, comparing neurofeedback 
to stimulant medication (short-acting methylphenidate), 
as stand-alone treatments on neurocognitive functioning. 
Furthermore, to control for non-specific treatment effects 
of neurofeedback, a physical activity training was applied 
as semi-active control condition. Accordingly, the physical 
activity training was matched to the neurofeedback training 
in terms of frequency and duration of the training sessions. 
By matching the training intensity of the neurofeedback 
and physical activity training, we aimed to control for non-
specific treatment effects, such as parental engagement and 
personal attention. Using a multicenter three-way parallel 
RCT design, the aim of the present study was to compare 
the three treatments: neurofeedback (NFB), stimulant med-
ication (MPH) and the semi-active control condition con-
sisting of physical activity (PA), in terms of their effects on 
neurocognitive functioning, as assessed using measures of 
attention, inhibition, and visual spatial working memory.
Methods
Participants
Eligible participants were Dutch speaking children, 
7–13 years of age, with a primary clinical DSM-IV-
TR diagnosis of ADHD [2]. Children with ADHD were 
recruited from fifteen child mental health outpatient care 
facilities in the West of the Netherlands. Before entering the 
study, parent- and teacher ratings on the Disruptive Behav-
ior Disorders Rating Scale (DBDRS) [32] confirmed their 
diagnosis; at least one of the scores on the Inattention or 
Hyperactivity/Impulsivity scales had to be above the 90th 
percentile for one of the informants, and above the 70th 
percentile for the other informant (signifying pervasive-
ness of symptoms). At study entry, all children were free of 
stimulant use for at least 1 month. Exclusion criteria were 
neurological disorders and IQ below 80 as measured by a 
four subtest version of the Wechsler Intelligence Scale of 
Children-III (WISC-III) including the subtests Vocabulary, 
Arithmetic, Block Design, and Picture Arrangement [33]. 
No restrictions were set on other comorbidities. Comorbid 
disorders were diagnosed according to DSM-IV-TR and 
retrieved from the medical records. Comorbid disorders 
included learning disorders (NFB; n = 5, MPH; n = 2, PA; 
n = 1), autism spectrum disorders, (NFB; n = 3, MPH; 
n = 2, PA; n = 3), anxiety disorders (NFB; n = 2, MPH; 
n = 0, PA; n = 2), and mood disorder (NFB; n = 1, MPH; 
n = 0, PA; n = 0). Chi-square test revealed no significant 
difference in the distribution of comorbid disorders over 
groups, χ2 (8, N = 112) = 12.88, p = 0.12.
Initially, 112 children with ADHD were randomized 
over the three interventions (NFB; n = 39; MPH; n = 36; 
PA; n = 37), with 103 children completing their interven-
tion (NFB; n = 38; MPH; n = 31; PA; n = 34). Drop-out 
reasons included motivational and/or practical reasons 
(NFB; n = 1, MPH; n = 3, PA; n = 3) and medical con-
traindications (MPH; n = 2). A participant flow diagram is 
presented elsewhere [34].
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Trial design
A multicentre three-way parallel group study with balanced 
randomization was conducted. A randomization table was 
created using a computerized random number genera-
tor [35]. Stocks of nine unmarked sealed envelopes were 
presented to parents at intake. Parents randomly picked an 
envelope revealing intervention allocation. Subsequently, 
children, parents, and teachers were aware of the allocated 
group. Data collection took place between September 2010 
and March 2014.
The current study aimed to enroll 186 participants. In 
total, 135 children with ADHD were assessed for eligibil-
ity and eventually 112 participants were randomized over 
the three interventions. To detect a medium effect size 
(f = 0.25) using three groups in a repeated measures (RM) 
analysis of variance (ANOVA) with an alpha 0.05 and a 
power of 95 %, a total sample size of 66 (i.e. 22 per group) 
was required [36]. Post-hoc comparisons of two groups 
required a total sample size of 54 (i.e. 27 per group) to 
detect a medium effect size (f = 0.25) in a RM ANOVA 
with an alpha 0.05 and a power of 95 %. In the current 
study, the smallest group size was 29. Consequently, all 
groups had enough participants to detect a medium effect 
size. Because in total 112 participants were randomized 
over the three groups instead of 186 participants, the cur-
rent study did not achieve the statistical power needed to 
detect smaller effect sizes than medium (f < 0.25) between 
groups. This report complies with the CONSORT 2010 
guidelines (Supplement Appendix 1) for reporting parallel 
group randomized trials [37]. The trial was registered on 
clinicaltrials.gov (Ref. No. NCT01363544).
Interventions
NFB and PA treatment consisted of three individual train-
ing sessions a week, with each session lasting 45 min 
including 20 min of effective training, over a period of 
10–12 weeks. All interventions, as described below, took 
place after the pre-intervention (t0) assessment.
Neurofeedback (NFB). Theta/beta training was applied 
with the aim to inhibit theta (4–8 Hz) and reinforce beta 
(13–20 Hz) activity at Cz. Theta/beta index was repre-
sented to the participant by simple graphics on a screen. 
Successful reduction of the theta/beta index as averaged 
over one trial relative to session baseline, was rewarded 
with the appearance of a sun and granted with credits. To 
promote generalization of the learned strategies into daily 
life, transfer trials were used. Transfer trials were presented 
without immediate visual feedback and were included from 
session 11 (25 %) and session 21 (50 %) onwards. To fur-
ther transfer learned behaviors, participants were instructed 
to retrieve their neurofeedback experiences by watching 
printed graphics of the training during school and home-
work. Compliance was verified by questioning the partici-
pants whether they used the transfer cards over the inter-
vention period. Transfer cards were used by 84 % of the 
participants. See also Supplement Appendix 2 for more 
detailed information about the neurofeedback intervention. 
The mean number of training sessions of participants who 
completed the assessments at post intervention (n = 38) 
was 29 (M = 28.53, SD = 2.63, range between 19 and 30).
Medication (MPH). After the pre-intervention assess-
ment, a 4-week double-blind randomized placebo-con-
trolled titration procedure was used to determine the 
optimal individual dose of short-acting methylphenidate 
(MPH) [38]. The 4-week titration phase was preceded by 
a baseline week to determine ADHD symptoms without 
MPH, and was followed by a lead-in week in which on 
three consecutive days, twice-daily (at breakfast and lunch 
time), doses of (1) 5 mg, (2) 10 mg, and (3) 15 mg (<25 kg 
body weight) or 20 mg MPH (>25 kg body weight) were 
used to assess possible adverse effects. During the 4 weeks 
titration phase, children received in pseudo-random order 
(1) 5 mg, (2) 10 mg, (3) 15 mg or 20 mg MPH or (4) pla-
cebo for 1 week, twice daily. During the titration phase, 
children, parents and teacher as well as the researchers 
were blind with regard to the prescribed dose. At the end 
of each week, parents and teacher were asked to evaluate 
inattention and hyperactivity/impulsivity symptoms on 
the DBDRS, and adverse effects on the MTA Side Effects 
Rating Scale [39]. In total, 31 children completed the titra-
tion procedure. Children were classified by a standardized 
procedure [40] as responders when their ADHD symptoms 
significantly decreased compared to placebo (n = 29). The 
standardized procedure [40] classified children as non-
responders when they did not show any decrease in inatten-
tion and hyperactivity/impulsivity symptoms across MPH 
doses and placebo as compared to baseline assessments 
(n = 2). When children were found to respond equally well 
across different MPH doses, the lowest MPH dose was pre-
scribed. The two non-responders were treated with 5 mg 
MPH twice daily. The child’s psychiatrist prescribed the 
optimal dose for the remaining intervention period (5 mg to 
10 children including 8 responders and 2 non-responders, 
10 mg to 14 children, 15 mg to 2 children, and 20 mg to 5 
children).
Physical activity (PA) as semi-active control condition. 
Maximum heart rate (HRmax) was determined before 
the start of the first training session. Each training ses-
sion started with 5 min of warming up, followed by five 
2-min moderate intensity exercises at a level of 70–80 % 
of HRmax. After a 5-min break, five 2-min vigorous inten-
sity exercises of 80–100 % of HRmax were performed. 
Each training finished with a 5-min cool down. Time and 
heart rate were monitored and registered using a POLAR 
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FT4 watch (Polar Electro Oy, Kempele, Finland). The 
mean number of sessions of participants who completed 
the assessments at post intervention (n = 34) was 28 
(M = 27.74, SD = 3.56, range 12–30).
Outcome measures
The auditory oddball task was used to measure atten-
tion [41]. This task contained 255 standard tones (523 Hz, 
85 %) and 45 target tones (1046 Hz, 15 %), presented 
pseudo-randomly for 100 ms. Children were instructed to 
attend to the stimuli and to press a button on a response box 
with the right index finger when they heard a target. Out-
come measures were response speed (mean reaction time; 
MRT), assessing attention, and the coefficient of variation 
(CV) [CV = MRT SD/MRT], a measure of attentional 
lapses [42]. Omission and commission errors were uncom-
mon and, therefore, excluded from analyses.
The stop-signal task (SST) was primarily used to meas-
ure inhibition [43]. This task required children to perform 
a binary-choice reaction time task using visual stimuli (go 
stimuli). Children were instructed to inhibit their response 
when a go stimulus was followed by a visual stop sig-
nal. A full description of the task can be found in Janssen 
et al. [44]. Variables of interest were: (1) stop-signal reac-
tion time (SSRT), a measure of the speed of the inhibitory 
process, calculated by subtracting mean stop-signal delay 
(SSD) from MRT; (2) number of commission on go trials, 
measuring impulsivity; (3) number of omission errors on 
go trials, assessing attention; (4) response speed (MRT), 
and (5) variability of response speed as calculated by coef-
ficient of variation (CV), measuring lapses of attention.
The visual spatial working memory task (VSWM) [45, 46] 
was assessed to measure short-term storage or maintenance 
of visual-spatial information (forward condition) and visuos-
patial working memory (backward condition). Children were 
instructed to repeat sequences of yellow circles, presented on 
a computer screen in a 4 × 4 grid, in a forward order (forward 
condition) and a reversed order (backward condition). Varia-
bles of interest were the number of correct trials per condition.
Procedure
The study was approved by the national medical ethics 
committee (NL 31641.029.10 CCMO). Written informed 
consent was obtained before participation from all parents 
and children aged 11 and older.
Pre-intervention (t0) assessment took place in the week 
prior to the start of the intervention. Post-intervention 
(t1) assessment took place 1 week after the last training 
session. Part of the data of this study are presented else-
where [34, 47]. During t1 assessment, the MPH-group 
continued use of medication. Due to technical problems 
or misinterpretation of the task, data of 23 participants for 
the oddball task and 10 participants for the stop-signal task 
were not available for analysis. Finally, data of 89 partici-
pants for the oddball task (NFB n = 30; MPH n = 29; PA 
n = 30) and 102 participants for the stop signal task (NFB 
n = 36; MPH n = 33; PA n = 33) were analyzed. Interven-
tions took place between September 2010 and March 2014.
Statistical methods
Statistical analyses were performed with the IBM SPSS 
Statistics, version 20.0 [48]. Differences between treatment 
groups in terms of background characteristics were ana-
lyzed with a Chi-square test or ANOVA with Tukey post 
hoc tests. Group characteristics and outcome measures 
were subjected to attrition analyses using ANOVA, com-
paring the initially randomized sample to the sample that 
completed the interventions.
To compare treatment effects, General Linear Model 
(GLM) repeated measures (RM) ANOVAs were applied, 
with time [between pre-intervention (t0) and post-inter-
vention (t1)] as within-subject factor and group (NFB, 
MPH and PA) as between-subject factor. For these analy-
ses, the adjusted difference at post-intervention [ADt1-t0] 
and accompanying 95 % confidence interval (95 % CI) 
and the accompanying effect size (partial eta squared, ηp
2) 
are reported. Effect sizes are expressed in percentage of 
explained variance in partial eta squared (ηp
2; with thresh-
olds for small, medium, and large effects corresponding to 
ηp
2 = 0.01, ηp2 = 0.06, and ηp2 = 0.14, respectively [49]. In 
case of significant time by group interactions, post hoc two-
way between-groups interactions analyses were performed 
separately for the between-subject factors (1) NFB and MPH, 
(2) MPH and PA and (3) NFB and PA with time (t0, t1) as 
within-subject factor. Only significant results of p ≤ 0.05 are 
reported. Intention-to-treat analyses were performed using 
imputation with Last Observation Carried Forward (LOCF). 
Complete case analyses were performed for participants who 
completed pre- and post-intervention assessments. Post hoc 
analyses were performed, with separate addition of assess-
ment site (Amsterdam or Rotterdam) and comorbid disorders 
(ADHD or ADHD with comorbid disorders). At group level, 
we found participants in the neurofeedback training were 
getting better at decreasing theta/beta ratio over time [50]. 
Therefore, to investigate the relation between getting better 
at decreasing theta/beta ratio (EEG slopes) and improvement 
in cognitive measures (difference scores), Pearson correla-
tions were computed. Decreased theta/beta ratio was rep-
resented by (1) theta slopes over runs (within sessions) and 
theta slopes over sessions and (2) beta slopes over runs and 
theta slopes over sessions. Improvement in cognitive meas-
ures was defined by difference scores (t1-t0) of the variables 
of interest as described above.




At pre-intervention, group characteristics, and both behav-
ioral and neurocognitive measures did not significantly dif-
fer between treatment groups (see Table 1).
Attrition analysis
No differences were found in group characteristics and 
pre-intervention measures between the participants as rand-
omized and the participants who completed the intervention.
Intention‑to‑treat analyses
Table 2 presents the results of the neurocognitive treat-
ment effects for the three intervention groups and statistical 
results of the group analyses.
Results on the oddball task, used to measure atten-
tion, showed a group by time interaction for MRT. Post-
hoc analyses revealed that the MPH group showed 
greater reductions of MRT over time than the NFB 
group, F(1,57) = 11.29, p = 0.001, ηp2 = 0.17, and PA 
group, F(1,57) = 19.90, p < 0.001, ηp2 = 0.26, suggest-
ing enhanced attention in the MPH group compared to 
the NFB and PA group. NFB and PA did not differ from 
each other, F(1,58) = 1.62, p = 0.21, ηp2 = 0.03. A main 
effect of time was found for CV in the absence of a signifi-
cant group by time interaction, indicating that all groups 
improved equally over time on this measure of attentional 
lapses.
A group by time interaction was found for SSRT 
measured with the SST. Post-hoc analyses revealed 
a greater reduction in SSRT for the MPH group than 
for both the NFB group, F(1,67) = 12.73, p = 0.001, 
ηp
2 = 0.16, and the PA group, F(1,64) = 15.76, p < 0.001, 
ηp
2 = 0.20, indicating faster inhibitory control processes 
Table 1  Group characteristics assessed pre-intervention (t0)
y years, DBDRS disruptive behaviour disorder rating scale, H/I hyperactivity/impulsivity scale, IQ intelligence quotient, SDQ strength and dif-
ficulty Questionnaire, SWAN strengths and weakness of ADHD symptoms and normal behaviour scale, SDSC sleep disturbance scale
a χ(2)
b NFB, n = 38; MPH, n = 35; PA, n = 35
c NFB: n = 39; MPH: n = 33; PA: n = 35
Total NFB MPH PA GROUP
df F p
n 112 39 36 37
Age in years, M (SD) 9.63 (1.76) 9.96 (1.88) 9.11(1.26) 9.80 (1.96) (2,109) 2.48 0.09
Gender, M/F 85/27 30/9 27/9 28/9 0.04a 0.98
IQ, M (SD) 99.75 (13.36) 100.56 (13.18) 101.11 (14.24) 97.57 (12.74) (2,109) 0.75 0.48
Parent ratings
 DBDRS
  Inattention (SD) 16.24 (5.30) 16.56 (5.10) 16.33 (5.65) 15.81 (5.26) (2,109) 0.20 0.82
  H/I (SD) 13.73 (6.12) 14.31 (6.03) 13.42 (6.40) 13.43 (6.03) (2,109) 0.26 0.77
 SDQ (SD) 16.60 (4.26) 16.90 (4.54) 15.64 (4.23) 17.22 (3.93) (2,109) 1.41 0.25
 SWAN
  Inattention (SD) 1.36 (0.64) 1.42 (0.52) 1.39 (0.70) 1.28 (0.70) (2,109) 0.51 0.61
  H/I (SD) 1.24 (0.75) 1.30 (0.70) 1.14 (0.72) 1.28 (0.82) (2,109) 0.48 0.62
  SDSC 45.45 (10.78) 45.32 (10.55) 45.09 (9.11) 44.97 (12.70) (2,105)b 0.06 0.94
Teacher ratings
 DBDRS
  Inattention (SD) 16.25 (5.78) 15.56 (5.36) 17.61 (6.30) 15.65 (5.63) (2,109) 1.48 0.23
  H/I (SD) 13.33 (8.07) 14.13 (7.12) 12.75 (9.70) 13.05 (7.44) (2,109) 0.30 0.74
 SDQ (SD) 14.65 (5.14) 14.51 (4.71) 13.48 (5.43) 15.91 (5.17) (2,104)c 1.96 0.15
 SWAN
  Inattention (SD) 1.43 (0.75) 1.40 (0.90) 1.52 (0.62) 1.38 (0.69) (2,104)c 0.34 0.71
  H/I (SD) 1.08 (1.03) 1.18 (0.92) 0.93 (1.25) 1.12 (0.92) (2,104)c 0.58 0.56
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in children in the MPH group compared to both the NFB 
and PA group. No differences were found between the 
NFB and PA group on SSRT, F(1,67) = 0.47, p = 0.49, 
ηp
2 < 0.01. Results of other measures of interest obtained 
from the SST, revealed a group by time interaction for 
commission errors. Post-hoc analyses demonstrated a 
trend towards larger decrease in commission errors for 
the MPH group than the NFB group, F(1,67) = 3.67, 
p = 0.060, ηp2 = 0.05. Furthermore, a significant larger 
decrease in commission errors was found for the MPH 
group compared to the PA group, F(1,64) = 10.72, 
p = 0.002, ηp2 = 0.14, together suggesting decreased 
impulsivity in the MPH group. No differences were found 
between the NFB and PA group on commission errors, 
F(1,67) = 1.62, p = 0.21, ηp2 = 0.02. A group by time 
interaction was also found for omission errors. Post-hoc 
analyses demonstrated a trend towards a larger decrease 
in omission errors for the MPH group than for the NFB 
group, F(1,67) = 3.47, p = 0.067, ηp2 = 0.05. In addition, 
a larger decrease in omission errors was found for the 
MPH group compared to the PA group, F(1,64) = 14.85, 
p < 0.001, ηp
2 = 0.19, suggesting improved attention in 
the MPH group. Analyses comparing the NFB and PA 
group on omission errors revealed a different pattern 
per group, F(1,67) = 4.60, p = 0.036, ηp2 = 0.06, with 
a slight (non-significant) increase in omission-errors 
over time for the PA group and a slight (non-significant) 
decrease in omission-errors over time for the NFB group. 
Main effects of time, without time by group interac-
tions, were found for the other two variables of atten-
tion, MRT and CV. These results indicate equal improve-
ments in all groups, with faster reaction times and less 
variable response speed at post-intervention compared to 
pre-intervention.
Results of the VSWM revealed a main effect of time 
on the forward and backward condition. In the absence of 
significant group by time interactions, indicating similar 
improvements over time for all three groups on short-term 
storage and working memory.
Complete case analyses
All analyses were rerun using complete case analysis and 
all significant findings were replicated with two excep-
tions: complete case analyses showed a significant larger 
decrease in both commission errors, F(1,61) = 5.63, 
p = 0.021, ηp2 = 0.08, and omission errors, F(1,61) = 5.36, 
p = 0.024, ηp2 = 0.08, for the MPH group compared to the 
NFB group, whereas these differences just escaped con-
ventional levels of significance in the intention-to-treat 
analyses. See also the Supplement Appendix 3 Table 1. 










































































































































































































































































































































































































































































 Eur Child Adolesc Psychiatry
1 3
Post hoc analyses for assessment location and comorbid 
disorders
Children who were assessed and had their intervention in 
Amsterdam did not differ over time from children who 
were assessed and had their intervention in Rotterdam on 
the neurocognitive outcome measures. Similarly, children 
with ADHD did not differ over time from children with 
ADHD and comorbid disorders.
Post hoc analyses EEG slopes and neurocognitive 
change
Analyses showed one negative correlation between beta 
slopes over sessions and change in SSRT (inhibitory con-
trol) as measured with the SST, r(36) = −0.39, p = 0.02. 
This result demonstrates that increase of beta over sessions 
correlates with improved inhibitory control at post-inter-
vention. See also the Supplement Appendix 4 Table 2.
Discussion
The present study compared neurofeedback as a stand-alone 
treatment to both stimulant medication and physical activity, 
acting as a semi-active control condition, on attention, inhi-
bition and working memory. These neurocognitive functions 
are often impaired in children with ADHD [10] and play 
key roles in explanatory models of the disorder [51]. Results 
of the current study indicated superior effects of stimulant 
medication compared to both neurofeedback and physi-
cal activity on our measure of attention, as shown by faster 
response speed on the oddball task in children taking meth-
ylphenidate than in children who received neurofeedback or 
physical activity training. Compared to both neurofeedback 
and physical activity, stimulant medication also had supe-
rior effects on inhibitory control, measured by stop-signal 
reaction time of the stop signal task. Working memory, as 
measured by visual spatial working memory, showed similar 
improvements from pre- to post-intervention across all three 
groups. Overall, the effects of neurofeedback on neurocogni-
tive functioning were comparable to the effects of our physi-
cal activity training acting as semi-active control condition.
One of the core deficits observed in ADHD are atten-
tion problems. In the current study, attentional function-
ing, as measured by response speed during the oddball 
task, showed greater improvements in children with ADHD 
receiving stimulant medication than in those receiving neu-
rofeedback or physical activity training. This result is in line 
with the behavioral findings of the current study, showing 
superior effects of stimulant medication compared to neu-
rofeedback in reducing parent as well as teacher reported 
attention problems [34]. Our findings are in line with the 
results of the only other available study comparing neuro-
feedback and stimulant medication on a task measuring 
attentional functioning [31]. The study of Ogrim and Hes-
tad [31] showed greater improvements in omission errors 
and reaction time variation on the Visual Continuous Per-
formance Task with stimulant medication than with neuro-
feedback. However, the three groups in the current study did 
not differ on the coefficient of variation in the oddball task. 
Indicating that although stimulant medication induced faster 
reaction times, the reactions did not become less variable. 
Although this seems in contradiction to the study of Ogrim 
and Hestad [31], note that the reaction time variation in 
the study of Ogrim and Hestad [31] did not control for the 
influence of response speed, whereas the current study did 
control for the influence of response speed using the coeffi-
cient of variation. Furthermore, our findings are in line with 
the results of two double blinded RCTs testing the effects 
of neurofeedback on a variety of attention paradigms, fail-
ing to demonstrate benefits of neurofeedback on attentional 
functioning compared to sham-neurofeedback in children 
with ADHD [19, 23]. Only the study by Bakhshayesh and 
colleagues [20] revealed superior effects of neurofeedback 
compared to EMG-biofeedback on neurocognitive measures 
of attention in children with ADHD using a single-blinded 
RCT design. To conclude, with the exception of the study 
by Bakhshayes et al. [20], all available studies support the 
conclusion of the current study, indicating that the effects 
of neurofeedback are insufficient to bring about improved 
attention as measured with neurocognitive tasks.
Similar to our findings on attention, stimulant medica-
tion induced larger improvements in inhibition, as reflected 
by decreased stop-signal reaction times (SSRT), compared 
to both the neurofeedback and our semi-active control con-
dition. This result is in accordance with our earlier EEG 
power spectra [47] and event-related potential (ERP) find-
ings [52], indicating specific neurophysiological effects 
during the stop task for stimulant medication compared to 
neurofeedback and physical activity while no effects were 
found for neurofeedback compared to physical activity. 
More specifically, ERP results indicated that medication 
induced increase in P3 amplitude strongly correlated with 
improved SSRT (r = −0.625). Inhibitory control defi-
cits have been considered as one of the central deficits in 
ADHD [3]. Our results of improved inhibition with stimu-
lant medication as compared to neurofeedback, are in line 
with behavioral results presented in the review of Arns 
et al. [53]. That review evaluated the effects of neurofeed-
back in ADHD and concluded that the effect size for neu-
rofeedback on symptoms of impulsivity was significantly 
lower compared to the effect size for methylphenidate on 
impulsivity [53]. In addition, the current study found com-
parable effects in inhibition in neurofeedback and the semi-
active control condition, suggesting that neurofeedback 
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does not impact on inhibition. Taken together, we conclude 
that neurofeedback has no specific effects on inhibition.
Both short-term storage and visuospatial working mem-
ory improved from pre- to post-intervention across all three 
groups. In line with our findings, studies comparing neuro-
feedback to sham-neurofeedback found comparable effects 
on verbal working memory over time [23, 28]. Furthermore, 
the study of Bink et al. [21], comparing treatment as usual 
combined with neurofeedback to treatment as usual, found 
similar improvements on verbal working memory. Our find-
ings, combined with results of these previous studies [21, 
23, 28], suggest that the improvement of working memory 
in children is related to practice effects which occur due to 
multiple testing, a problem that has often been reported 
with repeated testing [54]. Note that apart from these prac-
tice effects found for working memory, we did find superior 
effects of stimulant medication on measures of attention, inhi-
bition, and impulsivity, indicating that the instruments used in 
the current study proved sensitive to treatment effects.
Overall, the present study found larger improvements in 
neurocognitive functioning with stimulant medication than 
with neurofeedback. The present study applied a double 
blind titration procedure to determine an optimal dose of 
stimulant medication while the neurofeedback intervention 
was not optimized to the child’s individual needs. There-
fore, one could argue that the results we found were due to 
the supremacy of the titration protocol. However, compared 
to the semi-active control condition we found no superior-
ity of neurofeedback. On top of that, there is an ongoing 
debate on the efficacy of various neurofeedback protocols. 
The current study used the theta/beta training protocol. This 
protocol is based on findings of increased theta (4–8 Hz) 
and decreased beta (13–20 Hz) in ADHD [16] and is often 
used in ADHD treatment with the aim to improve atten-
tion [18]. The question, however, is whether this protocol is 
effective for the treatment of neurocognitive dysfuntioning 
in children with ADHD. Bink et al. [21] already pointed out 
that the majority of studies that failed to show any effects 
of neurofeedback, used a somewhat different protocol com-
pared to the study of Bakhshayes et al. [20], the only single-
blinded study that found improvements on neurocognitive 
attention measures thus far. In the study of Bakhshayes et al. 
[20], a neurofeedback protocol was used which rewarded 
not only suppression of theta, but also high beta (16–20 Hz). 
Rewarding these higher beta-band frequencies may underlie 
the positive effects found in the study of Bakhshayes et al. 
[20]. However, despite the fact that the neurofeedback train-
ing used in the current study also encompassed higher beta 
frequencies (16–20 Hz), we found no positive effects for 
neurofeedback compared to stimulant medication.
The present study examined the effects of neurofeed-
back on neurocognitive functioning compared to stimu-
lant medication as well as a semi-active control condition. 
As we found theta and beta learning effects in participants 
that received neurofeedback [50], we were interested in 
exploring the relation between these learning effects and 
improvement in cognitive measures. Results showed one 
significant relation between increase of beta over sessions 
and improved inhibitory control at post intervention. How-
ever, note that we might have a multiple testing problem 
as we tested 36 correlations and found only one significant 
outcome, which may be a chance finding. Therefore, this 
result should be interpreted with caution. Further, this RCT 
study successfully allocated participants randomly to the 
three intervention groups and sample sizes were adequate to 
detect medium sized effects. Still, a few points need con-
sideration when interpreting the current findings. First, in 
the current study, physical activity was implemented as a 
semi-active control condition where frequency and intensity 
of the training were similar to the neurofeedback interven-
tion. The review of Halperin, Berwid, and O’Neill [55] sug-
gested positive effects with more intensive physical activity 
on children’s ADHD-related behaviors. Thus, it might be 
argued that our semi-active control condition might have 
exerted beneficial effects on neurocognitive functioning of 
our participants, and thus might not have been the optimal 
comparison condition. However, children in the physical 
activity intervention received only 2-min bounds of physi-
cal activity during a time period of only 20 min. The use 
of 2-min bounds of physical activity does not correspond 
with the recommendations on physical activity found in the 
literature [55]. Therefore, it does not seem likely that the 
physical activity protocol we used exerted beneficial effects 
on neurocognitive functioning. More research on physi-
cal activity is necessary to substantiate its possible chronic 
effects on the problem behavior of children with ADHD. 
Second, it could be argued that expectation might have had 
a large influence on the results [56]. Therefore, expectations 
of parents and teachers at pre-intervention were assessed. 
Results showed that only in the neurofeedback intervention, 
parents with higher treatment expectations of neurofeed-
back rated their child as more improved in terms of inatten-
tive symptoms. Stimulant medication and physical activity 
revealed no association between expectancy and reported 
changes [34]. Third, the current study found superior effects 
of stimulant medication on neurocognitive functioning com-
pared to a neurofeedback training of theta/beta frequen-
cies in children with ADHD. However, the proposition that 
increased theta/beta ratio may be considered as biomarker 
for ADHD has been challenged by recent research [57, 58] 
and other neurofeedback protocols such as slow cortical 
potentials (SCP) training are suggested for the treatment of 
ADHD [59]. SCP is not the only alternative neurofeedback 
protocol. Because frequency band and SCP neurofeedback 
are often criticized for the large time investment, with many 
studies using 30 sessions, new neurofeedback methods such 
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as near-infrared spectroscopy (NIRS) are proposed. A recent 
pilot study compared the effects of 12 sessions of SCP and 
NIRS, and found promising effects for NIRS on parent-, 
teacher ratings and improvement on an attention test [60]. 
Nevertheless, the effectiveness of both SCP and NIRS as a 
treatment for children with ADHD needs to be confirmed 
by randomized controlled studies using larger sample sizes. 
Clearly, more research on the specificity of the various neu-
rofeedback protocols is recommended.
In conclusion, stimulant medication showed superior 
effects over neurofeedback on improving neurocognitive 
functions, and in particular on attention and inhibition. The 
effects of neurofeedback on neurocognitive functioning 
were comparable to the semi-active control condition, indi-
cating that for neurofeedback showed no specific effects 
on neurocognitive functioning. Hence, results of the cur-
rent RCT do not support the use of theta/beta training as a 
stand-alone treatment to improve neurocognitive function-
ing in children with ADHD.
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